Allergic asthma is a chronic lung disease resulting from an inappropriate T helper (Th)-2 response to environmental antigens. Early tolerance induction is an attractive approach for primary prevention of asthma. Here, we found that breastfeeding by antigen-sensitized mothers exposed to antigen aerosols during lactation induced a robust and long-lasting antigen-specific protection from asthma. Protection was more profound and persistent than the one induced by antigen-exposed non-sensitized mothers. Milk from antigen-exposed sensitized mothers contained antigen-immunoglobulin (Ig) G immune complexes that were transferred to the newborn through the neonatal Fc receptor resulting in the induction of antigen-specific FoxP3 + CD25 + regulatory T cells. The induction of oral tolerance by milk immune complexes did not require the presence of transforming growth factor-in milk in contrast to tolerance induced by milk-borne free antigen. Furthermore, neither the presence of IgA in milk nor the expression of the inhibitory Fc RIIb in the newborn was required for tolerance induction. This study provides new insights on the mechanisms of tolerance induction in neonates and highlights that IgG immune complexes found in breast milk are potent inducers of oral tolerance. These observations may pave the way for the identification of key factors for primary prevention of immune-mediated diseases such as asthma.
INTRODUCTION
Early life is a challenging period for the immune system: it faces massive antigenic challenge due to microbial colonization and exposure to environmental antigens and at the same time has to maintain low levels of inflammation to allow harmonious organ development. Pioneer studies by Medawar have suggested that neonates are immunologically immature and prone to tolerance induction. Later works showed that neonates are biased for T helper (Th)-2 responses as compared to adults but also that any kind of immune response could be induced in neonates under appropriate condition. 1 How the immune system responds to antigenic challenge in early life probably influences susceptibility to immune-mediated disorders and in particular to those that develop in childhood such as autoimmune diabetes and allergic diseases. 2 Among allergic diseases, allergic asthma is a major public health concern affecting 300 million people and belonging to the leading causes of morbidity in children. 3 The pathogenesis of this chronic lung inflammatory disease involves a sensitization step where CD4 + T cells are primed in response to normally innocuous inhaled allergens and differentiate toward a Th2 phenotype. Some of these sensitized patients will develop asthma, a disease that is characterized by acute respiratory difficulties after allergen inhalation due to mucus accumulation and airway inflammation and more chronic symptoms due to lung remodeling. 4, 5 Early immune modulation aimed at impeding allergen sensitization is an attractive approach for primary prevention of asthma.
For years, breast milk was considered mainly as a source of nutrients for the developing child. The extensive observations that breastfeeding affords protection toward infectious diseases and reduces mortality due to common infections by more than half have added another key role to breastfeeding. 6 Protection mainly relies on passive immunity due to the transfer of high Breast milk immune complexes are potent inducers of oral tolerance in neonates and prevent asthma development amounts of microbe-specific immunoglobulin (Ig) that compensate for the deficiency of Ig synthesis during the first year of life. 7 In addition, recent studies have shown that breastfeeding actively shapes progeny ' s immune response both through its effect on gut flora and through the transfer of various immune mediators. 6 Epidemiological studies on the protection from allergic diseases upon breastfeeding have yielded conflicting results, whether or not the allergic status of the mothers was taken into account. 8 -11 In a meta-analysis of prospective studies 10 and in a multidisciplinary review 8 of studies performed between 1966 and 2000, the authors concluded that breastfeeding protection was higher in the subgroup of children with a positive family history of asthma or atopy. Two more recent prospective studies on a birth cohort of 4,089 (ref. 12 ) and 3,115 children, 13 respectively, did not show increased protection in the case of heredity for allergy. Finally, in a prospective study on 1,200 children, breastfeeding did not protect children against atopy or asthma and could even increase the risk of asthma in children with a parental history of asthma. 14 Of note, allergen exposure of the mothers was not recorded in these studies. We have recently formulated the hypothesis that protection from asthma through breastfeeding relies on immune tolerance induction and requires antigen transfer to the child through breast milk. 15 In a mouse model, we have shown that protection against asthma through breastfeeding required the exposition of the mothers to the allergen during lactation. The presence of the allergen together with transforming growth factor-(TGF-) in breast milk was necessary to induce the development of regulatory T (T reg ) cells in the progeny and their partial protection from asthma development. In that study, mothers were not sensitized to the inhaled antigen. Here, we have investigated whether breastfeeding by allergic mothers would affect asthma development in the progeny.
RESULTS

Breastfeeding by antigen-exposed sensitized mothers induces a profound and long-lasting antigen-specific protection from allergic airway inflammation
The development of the newborn immune system is influenced by maternal factors that are transferred from the mother to the progeny in utero and through breastfeeding. To assess whether allergic mothers can induce protection from allergic airway inflammation through breast milk, we fostered pups born from naive mothers by non-sensitized or ovalbumin (OVA)-sensitized mothers that were exposed or not to OVA aerosols during lactation. These mothers will be referred as " OVA-exposed " or " unexposed " , " sensitized " or " non-sensitized " thereafter ( Figure 1a ). When 6 -8 weeks old, fostered mice were sensitized, challenged with OVA aerosols, and analyzed for features of allergic airway disease ( Figure 1a ). As we previously published, mice breastfed by OVA-exposed nonsensitized mothers were partially protected from asthma 15 ( Figure 1b -f ). Although mice breastfed by unexposed sensitized mothers were not protected, exposition of sensitized mothers to OVA aerosols during lactation resulted in a profound and reproducible inhibition of allergic airway disease in the breastfed pups. Airway hyperreactivity was dramatically reduced even in response to high doses of methacholine ( Figure 1b ) ; total cell and eosinophil numbers in bronchoalveolar lavage (BAL) fluids were similar to those found in naive mice ( Figure 1c ) ; secretion of interleukin (IL)-4, IL-5, IL-10, and IL-13 by lung cells was greatly inhibited ( Figure 1d ); serum OVA-specific IgE, IgG1, and IgG2a were close to the lower limit of detection ( Figure 1e ); and lung inflammation was extremely scarce ( Figure 1f ). TGF-and interferon-levels were similar in all groups (data not shown). Strikingly, all parameters of allergic airway disease were more profoundly inhibited in mice breastfed by OVA-exposed sensitized mothers as compared to those breastfed by OVA-exposed non-sensitized mothers: 62 vs. 42 % of inhibition for resistance at the highest methacholine concentration; 96 vs. 76 % for eosinophilic airway inflammation; 94 vs. 67 % for OVA-specific IgE levels; 80 vs. 70 % for lung IL-4 levels, 66 vs. 44 % for IL-5, 72 vs. 45 % for IL-10, and 88 vs. 54 % for IL-13.
To assess whether protection was long lasting, we immunized mice breastfed by OVA-exposed sensitized or non-sensitized mothers 14 weeks after birth and challenged them with OVA aerosols. Representative features of allergic airway disease such as eosinophilic airway inflammation, serum levels of OVA-specific IgE, and lung IL-13 and IL-5 secretion Figure 1 Allergic airway disease in mice breastfed by ovalbumin (OVA)-exposed sensitized mothers. ( a ) Schematic representation of the experimental protocol. Adult BALB / c female mice were sensitized or not with two injections of OVA in alum before mating. Pups from sensitized mothers were killed at birth and replaced by pups from non-sensitized mothers. Non-sensitized and sensitized mothers were then exposed or not exposed to OVA aerosols every other day from delivery until weaning. When 6-to 8-week-old, offspring were sensitized with two intraperitoneal injections of OVA in alum and challenged daily for 5 days with OVA aerosols. Mice were analyzed 1 day after the last aerosol. ( b ) Airway hyperreactivity (AHR). Dynamic lung resistance and compliance were monitored in mice breastfed by unexposed (filled circle) or OVA-exposed (empty circle) non-sensitized mothers, or unexposed (filled square) or OVA-exposed (empty square) sensitized mothers upon sensitization and challenge with OVA; n = 6 -7 mice per group in each experiment. Non-sensitized mice challenged with OVA (triangle) were used as controls; n = 3 in each experiment. Data are expressed as mean ± s.e.m. and are representative of one experiment out of two. * * P < 0.01. ( c -e ) OVA-sensitized and challenged mice breastfed by unexposed (empty bars) or OVA-exposed (light gray bars) non-sensitized mothers, or unexposed (dark gray bars) or OVA-exposed (black bars) sensitized mothers were analyzed for allergic airway inflammation. Non-sensitized mice challenged with OVA (hatched bars) were used as controls. Number and phenotype of cells in bronchoalveolar lavage (BAL) fluids ( c ), cytokine secretion by lung cells incubated or not with OVA ( d ), and serum levels of OVA-specific Ig ( e ). Data are expressed as mean ± s.e.m. of seven experiments with n = 6 -8 mice per group in each experiment. * * * * P < 0.0001; * * * P < 0.001; * * P < 0.01; * P < 0.05; NS, P > 0.05. remained profoundly decreased in mice breastfed by OVAexposed sensitized mothers but not in those breastfed by OVA-exposed non-sensitized mothers ( Figure 2a -c ) . Further experiments showed that mice breastfed by OVA-exposed sensitized mothers were protected from allergic airway disease induced by OVA, but not by the unrelated Leishmania LACK antigen 16 ( Figure 2d -f ) . Therefore, breastfeedinginduced protection conferred by OVA-exposed sensitized mothers was antigen specific. Altogether, our data show that breastfeeding by antigen-sensitized mothers induces a profound, reproducible, and long-lasting antigen-specific protection as far as the mothers are exposed to the antigen during lactation. IgA exert an immunoregulatory role in mice and are associated with immune tolerance in humans. 17 -20 OVA-specific IgA were found in the milk of OVA-exposed sensitized mothers, but not in those of unexposed sensitized mothers or OVA-exposed or unexposed non-sensitized mothers ( Table 1 ). To further assess the role of IgA in breastfeeding-induced protection, we used a neutralizing anti-CCL28 monoclonal antibody (mAb) that blocks the accumulation of IgA-secreting cells in the mammary gland and thereby IgA secretion into milk. 21 Administration of anti-CCL28 mAb to OVA-exposed sensitized mothers during lactation resulted in a drop of total IgA in milk from 131 to Breast milk from unexposed or OVA-exposed non-sensitized or sensitized mothers was collected, pooled, and analyzed for the presence of OVA-specifi c IgA, IgG2a, and IgG1 by ELISA. Data show the mean ± s.e.m. of six experiments.
18 g ml − 1 and in a reduction of OVA-specific IgA from 25 to 1.4 g ml − 1 (pool of three individuals). Mice breastfed by anti-CCL28 mAb-treated OVA-exposed sensitized mothers remained protected as shown by measuring airway eosinophilia, serum levels of OVA-specific IgE, and IL-5 and IL-13 secretion in their lungs ( Figure 3a -c ).
Breast milk contains high levels of the immunosuppressive cytokine TGF-. 6 To investigate the role of TGF-in breastfeeding-induced tolerance by sensitized mothers, we treated OVA-exposed sensitized mothers with anti-TGF-or control isotypic mAb during lactation. As previously published, the intraperitoneal administration of 1 mg of anti-TGF-mAb to lactating mothers twice a week resulted in a nearly total neutralization of milk TGF-. 15 Eosinophil numbers in BAL fluids, OVA-specific IgE levels in serum, and IL-13 and IL-5 lung secretion were similarly decreased in mice breastfed by OVA-exposed sensitized mothers treated with anti-TGF-or control isotypic mAb ( Figure 3d -f ). Therefore, milk-borne TGF-was not necessary for breastfeeding-induced protection by OVA-exposed sensitized mothers. In addition, when OVA-exposed sensitized mothers were treated with anti-TGF-mAb, OVA-specific IgA levels in milk were greatly reduced (0.6 vs. 25 g ml − 1 , pool of three individuals) further showing that OVA-specific IgA were not required for breastfeeding-induced protection by OVA-exposed sensitized mothers.
Milk of OVA-exposed sensitized mothers contains OVA -IgG immune complexes
Circulating maternal IgG have been proposed to inhibit Th2 responses in the offspring of antigen-sensitized rodents. 5,22 -28 Therefore, we measured the levels of OVA-specific IgG in the milk of OVA-exposed sensitized mothers and in the sera of their breastfed pups. Both OVA-specific IgG1 and IgG2a were present in the milk of OVA-exposed sensitized mothers ( Table 1 ). The levels of OVA-specific IgG1 were 20-fold higher than those of IgG2a ( Table 1 ) . Moreover, OVA-specific IgG1 levels were 20-fold higher in the milk of OVA-exposed sensitized mothers than in unexposed sensitized mothers and close to or below the lower limit of detection in OVA-exposed and unexposed nonsensitized mothers ( Table 1 ) . OVA-specific IgG1 and IgG2a were also found in sera of pups breastfed by OVA-exposed sensitized mothers ( Table 2a and b ). OVA-specific IgG2a levels were only found in sera before weaning and at levels 50 times lower than those of IgG1 ( Table 2a ) . Although high levels of OVA-specific IgG1 were found in the serum of 2-week-old newborns pups breastfed by OVA-exposed sensitized mothers (11 ± 1.9 mg ml − 1 ; mean ± s.e.m.; n = 6), this level dropped to 0.2 mg ml − 1 at 6 -8 weeks and OVA-specific IgG1 were undetectable at 14 weeks ( Table 2b ). Because breastfeeding-induced protection by OVAexposed sensitized mothers was still effective in 14-week-old mice ( Figure 2a ), this latter result suggests that circulating OVAspecific IgG were not directly responsible for the inhibition of Th2 responses in mice that have been breastfed by OVA-exposed sensitized mothers. We next assessed whether OVA was present in the milk of OVA-exposed sensitized mothers. OVA was readily detected both by enzyme-linked immunosorbent assay (ELISA) and by western blot analysis ( Figure 4a ). As previously published, 15 we also found that OVA was present in the milk of OVAexposed non-sensitized mothers. OVA levels in milk were 10-fold lower in sensitized mothers than non-sensitized mothers (29 ± 8 vs. 342 ± 21 ng ml − 1 ; mean ± s.e.m.; n = 6). As the milk of OVA-exposed sensitized mothers contained both OVA and OVA-specific IgG, we investigated whether it also contained OVA -IgG immune complexes. OVA -IgG1 immune complexes were readily detected in the milk of OVA-exposed sensitized mothers and at much lower levels in the milk of OVA-exposed non-sensitized mothers ( Figure 4b , left panel). To determine the proportion of OVA that was engaged in immune complexes, we depleted the milk of OVA-exposed sensitized mothers of IgG with protein G before being analyzed by western blot using an anti-OVA mAb. Results showed that 85 % of OVA was bound to IgG in the milk of OVA-exposed sensitized mothers ( Figure 4b , right panel). Molecular size of OVA -IgG immune complexes was determined after gel filtration of the milk from OVA-exposed sensitized mothers and analysis by ELISA for the presence of OVA -IgG1 immune complexes in the collected fractions ( Figure 4c ). OVA -IgG1 immune complexes were found in the fractions corresponding to proteins of 500 -2,000 kDa molecular weight. Further experiments showed that OVA -IgG1 immune complexes were present in the serum of 2-week-old pups breastfed by OVA-exposed sensitized mothers ( Figure 5a ).
FcRn is necessary for breastfeeding-induced protection by OVA-exposed sensitized mothers
The expression of the neonatal Fc receptor (FcRn) on epithelial cells in the small proximal intestine allows an active and protected transport of maternally derived IgG from breast milk to the pups. 29, 30 FcRn is expressed on intestinal epithelial cells in rodents until weaning and in humans throughout life. In adult transgenic mice expressing the human FcRn, this receptor allows the transfer of IgG immune complexes across the intestinal barrier allowing subsequent retrieval of luminal antigens. 31 The presence of OVA -IgG immune complexes in the serum of 2-week-old pups breastfed by OVA-exposed sensitized mothers shows a protected transfer of these immune complexes from mother ' s milk to their pup and suggests a role for the FcRn in this transport ( Figure 5a ). Accordingly, we observed that the levels of OVA -IgG immune complexes were profoundly decreased in the serum of FcRn-deficient mice breastfed by OVA-exposed sensitized mothers indicating a crucial role for this receptor in the transfer OVA -IgG immune complexes from mother ' s milk to the pup ( Figure 5a ). Because OVA was almost entirely found associated to immune complexes in the milk of OVA-exposed sensitized mothers, we predicted that FcRn-deficient mice would not become tolerant to OVA when breastfed by OVA-exposed sensitized mothers. To test this hypothesis, we fostered FcRn-deficient and wild-type (wt) C57Bl / 6 pups by unexposed and by OVA-exposed sensitized mothers. Similar to BALB / c mice, C57Bl / 6 breastfed by OVA-exposed sensitized mothers were protected from allergic airway disease development as shown by a decrease in eosinophilic airway inflammation, IL-5 and IL-13 lung secretion, and serum OVA-specific IgG1 (IgE are not detected in C57Bl / 6 mice in the model we use for asthma induction) as compared to mice breastfed by unexposed sensitized mothers ( Figure 5b -d ) . In contrast, protection was totally abrogated in FcRn-deficient mice breastfed by OVAexposed sensitized mothers ( Figure 5e -g ). This latter result was not due to an intrinsic inability of FcRn-deficient mice to mount tolerance as FcRn-deficient mice were tolerant when breastfed by OVA-exposed non-sensitized mothers ( Supplementary  Figure 2 ) . These data strongly suggest that the FcRn-mediated transfer of OVA -IgG immune complexes from mother ' s milk to their pups is critical for tolerance induction by OVA-exposed sensitized mothers.
Fc ␥ RIIb is not required for breastfeeding-induced protection by OVA-exposed sensitized mothers Fc RIIb (CD32b) belongs to the family of immune inhibitory receptors that carry an immunoreceptor tyrosine-based inhibition motif. When colligated to the B-cell receptor, The sera of newborns breastfed by unexposed or OVA-exposed non-sensitized or sensitized mothers were harvested 2, 7, and 14 weeks after birth and analyzed for the presence of OVA-specifi c IgG2a ( Table 2a ) and IgG1 ( Table 2b ) by ELISA. Data are expressed as mean ± s.e.m. with n =9.
Fc RIIb inhibits B-cell activation and proliferation, induces apoptosis, and is critical for B-cell tolerance to self-antigens as shown by the development of lupus-like disease in Fc RIIb-deficient mice. Fc RIIb is also involved in T-cell tolerance through its expression on dendritic cells (DCs). 32 -35 To assess whether Fc RIIb is involved in tolerance induced by OVA-exposed sensitized mothers, wt C57Bl / 6 mice or Fc RIIb-deficient pups were breastfed by OVA-exposed or For western blot, the milk from unexposed (lanes 1, 3, and 5) and from OVA-exposed (lanes 2, 4, and 6) sensitized mothers was analyzed directly (lanes 1 and 2) or after removal of protein G-bound material (lanes 3 and 4) . Protein G-bound material was eluted and analyzed (lanes 5 and 6). OVA in phosphate-buffered saline (PBS) was used as a control (left lane). One representative experiment out of two is shown. * * P < 0.01. ( c ) Levels of OVA -IgG immune complexes and OVA-specific IgG in FPLC fractionated milk. The milk from OVA-exposed sensitized mice was fractionated on FPLC and the fractions corresponding to proteins of the indicated MW were collected and analyzed by ELISA for the presence of OVA-specific IgG1 (dashed line) and OVA -IgG1 immune complexes (solid line). Data show the results of one representative experiment out of four for the milk of OVA-exposed sensitized mice. When the milk of naive mice was analyzed, none of the fractions gave a positive signal.
unexposed sensitized mothers. Similar to wt C57Bl / 6 ( Figure  5b -d ) , Fc RIIb-deficient mice breastfed by OVA-exposed sensitized mothers were protected from allergic airway disease as shown by reduced airway eosinophilia, serum levels of OVA-specific IgG1, and IL-5 and IL-13 lung secretion ( Figure 5h -j ) . Therefore, breastfeeding-induced protection by OVA-exposed sensitized mothers is independent of the inhibitory Fc RIIb. 
Fc RIIb-deficient ( h -j ) C57BL / 6 pups were breastfed by unexposed (dark gray bars) or OVA-exposed (black bars) sensitized mothers. Non-sensitized mice challenged with OVA were used as controls (hatched bars). Data show cell number and eosinophils frequency in bronchoalveolar lavage (BAL) fluids ( b , e , and h ), serum levels of OVA-specific IgG ( c , f , and i ), and levels of IL-5 and IL-13 secreted by lung cells when incubated with OVA ( d , g , and j ). Data are expressed as mean ± s.e.m. of five experiments for wild-type C57BL / 6 and two experiments for FcRn-deficient and Fc RIIB-deficient mice with n = 6 -8 mice per group in each experiment. * * * * P < 0.0001; * P < 0.05; NS, P > 0.05.
the proliferation of OVA-specific T lymphocytes and their differentiation into FoxP3 + T reg cells. We first incubated bone marrow-derived dendritic cells with milk from OVA-exposed or unexposed sensitized mothers and OVA-specific T-cell receptor (TCR) transgenic DO11.10 CD4 + T cells. We found that 71 % of T cells had divided upon incubation with milk from OVAexposed sensitized mothers, whereas no proliferation occurred in the presence of milk from unexposed mothers ( Figure 6a ). Furthermore, milk from OVA-exposed, but not from unexposed, mothers induced the differentiation of FoxP3 + T cells (1 ± 0.1 vs. < 0.1 % ) ( Figure 6c ). The 500 -2,000 kDa molecular weight milk fractions from OVA-exposed mothers that contained OVA -IgG immune complexes also induced T-cell proliferation and T reg differentiation whereas the corresponding fractions from unexposed mothers did not ( Figure 6b and d ) . Therefore, OVA -IgG immune complexes readily induced the proliferation of OVA-specific T cell and their differentiation into FoxP3 + T cells. We next assessed whether the transfer of milk-borne OVA -IgG immune complexes to the pup could induce the generation of OVA-specific T reg cells in vivo . Therefore, we injected 1-day-old BALB / c newborns with CD4 + T cells purified from the spleens of OVA-specific DO11.10 TCR transgenic RAG-2-deficient neonates. Injected mice were then breastfed by OVA-exposed or unexposed sensitized mothers. Ten days after weaning, the presence of TCR transgenic CD4 + T cells was assessed in peripheral and mesenteric lymph nodes and in spleen using the clonotypic mAb KJ1.26. Although the frequency of TCR transgenic CD4 + T lymphocytes in the peripheral lymph node and the spleen of mice breastfed by OVA-exposed and unexposed sensitized mothers was below 0.2 % (data not shown), it reached 1.3 % in the mesenteric lymph nodes of mice breastfed by OVA-exposed sensitized mothers as compared to 0.2 % in those breastfed by unexposed sensitized mothers ( Figure 7a ).
Furthermore, the frequencies of KJ1.26 + TCR transgenic CD4 + T cells that were FoxP3 + or CD25 + were 2-to 3-fold higher in mice breastfed by OVA-exposed sensitized mothers than in those breastfed by unexposed sensitized mothers ( Figure 7b and c ) . In contrast, the frequencies of endogenous KJ1.26 − CD4 + T cells that were FoxP3 + or CD25 + were similar in both groups. These data indicate the preferential expansion of OVA-specific CD4 T lymphocytes in mice breastfed by OVA-exposed sensitized mothers and their conversion to a regulatory phenotype.
We next injected OVA-specific OTII TCR transgenic Ly5.1 + CD4 + T lymphocytes into either wt or FcRn-deficient C57BL / 6 pups. As observed when T cells from DO11.10 transgenic mice were injected into BALB / c mice ( Figure 7c ), T cells from OTII transgenic mice converted to FoxP3 + cells in the MLN of wt C57BL / 6 mice breastfed by OVA-exposed sensitized mice ( Figure 7d ). In contrast, OTII cells were not induced to express FoxP3 when injected into FcRn-deficient mice ( Figure 7d ) . Therefore, the ability of milk-borne OVA -IgG immune complexes to induce T reg differentiation was FcRn dependent.
To further show the role of CD25 + T cells in breastfeedinginduced protection by OVA-exposed sensitized mothers, we injected mice breastfed by OVA-exposed or unexposed sensitized mothers before OVA sensitization with anti-CD25 mAb. As observed in other asthma models, 36 this treatment resulted in increased allergic airway inflammation in mice breastfed by unexposed sensitized mothers ( Figure 8a -c ) . The levels of inhibition of allergic airway inflammation induced by OVA-exposed sensitized mothers were reduced in mice treated by anti-CD25 mAb as compared to those treated by rat IgG1: 27 vs. 88 % inhibition for eosinophilia; 83 vs. 98 % inhibition for OVA-specific IgE, 18 vs. 70 % for lung IL-5 secretion, and 36 vs. 80 % for lung IL-13 secretion ( Figure 8a -c ) . Thus, CD25 + CD4 + T reg cells are involved in breastfeeding-induced protection induced by OVA-exposed sensitized mothers. 
DISCUSSION
In this study, we observed that breastfeeding by antigen-exposed sensitized mothers abolished asthma development in the progeny. In contrast to the protection afforded by antigen-exposed non-sensitized mothers, protection conferred by sensitized mothers was much more profound, long lasting, did not require the presence of TGF-in milk, and relied on the development of CD25 + CD4 + T reg cells.
Breastfeeding-induced inhibition of Th2 immune responses in rodents fostered by antigen-sensitized mothers has been extensively studied. 5,22 -28,37 It was proposed that this phenomenon was dependent on the induction of antigen-specific IgG following maternal immunization and their transfer to the neonates through breast milk. Proposed mechanisms included interference with the neonatal idiotypic network, masking of antigenic determinants, formation of immune complexes at the time of antigen sensitization leading to antigen clearance, and engagement of the inhibitory receptor Fc RIIB on B lymphocytes or DCs. 22,24 -27 In most studies, protection lasted less than 6 weeks and vanished when maternal IgG were cleared. 24, 26 In contrast with these studies, we have observed that mice breastfed by OVA-exposed sensitized mothers remained protected after OVA-specific IgG had disappeared from circulation. Instead of being directly responsible for tolerance induction, our data suggest that IgG induce active and profound antigen-specific tolerance in the breastfed pup through the generation of milk immune complexes.
How could milk immune complexes induce tolerance in the breastfed pups? Thirty years ago, an elegant study reported that in vitro -made antigen-IgG complexes were transferred much more efficiently across the epithelial barrier of neonatal rats than free antigen. 38 The antigen was found in coated vesicles in epithelial cells and transferred to extracellular spaces only in the presence of antigen-specific IgG. Further studies showed that antigen transfer required the Fc portion of IgG. Accordingly, neonatal oral tolerance could be induced to human IgG that were efficiently transferred across the epithelial barrier, but not to OVA that is not. 39 Other studies identified FcRn as the receptor allowing an active and nondegradative transfer of IgG across the proximal small intestine. 29, 30, 40 Here, we observed that milk-borne OVA -IgG complexes were actively transferred from the mother to the pup through the FcRn. Furthermore, the FcRn-mediated transfer of OVA -IgG complexes resulted in the induction of FoxP3 + T reg and FcRn-deficient mice breastfed by OVA-exposed sensitized mice were not protected from allergic airway disease. Altogether, our data show that milk-borne antigen-IgG immune complexes were efficiently transferred to the breastfed pup through the FcRn and, most importantly, that this phenomenon resulted in the induction of active tolerance.
Immune complexes can lead to severe inflammation and tissue damage as observed in erythematous lupus or poststreptococcal glomerulonephritis. In other settings, immune complexes can also suppress immune responses. This was shown both in mice 41 -43 and in humans. 44, 45 Saint-Remy and his colleagues showed some years ago that patients suffering from allergic bronchial asthma to Dermatophagoides could be efficiently treated by inoculation of allergen -IgG immune complexes. 44 We have observed that the transfer of OVA -IgG immune complexes from the mother to the neonate resulted in the expansion of OVA-specific T reg cells and protection from allergic airway disease. The exposition of newborns to immune complexes through the gut is likely to be important in this process as the gut-associated lymphoid tissues are specialized in tolerance induction. 46 ,47 Surprisingly, we have found that the inhibitory receptor Fc RIIB that is involved in both B-and T-cell tolerance was not necessary for tolerance induction in pups breastfed by OVA-exposed sensitized mothers. The ability of milk immune complexes to induce tolerance and not inflammation may also rely on their biochemical characteristics. Thus, we found that milk-borne OVA -IgG immune complexes induced the differentiation of naive OVA-specific T cells into FoxP3 + T reg in vitro . Immune complexes formed in the excess of antibody are immunosuppressive whereas they are immunogenic when the antigen is in excess. 42 In the case of immune complexes found in the milk of OVA-exposed sensitized mothers, antibodies are in large excess as OVA-specific IgG1 levels are in the range of 100 g ml − 1 and OVA levels in the range of 100 ng ml − 1 . Other biochemical characteristics such as antibody glycosylation have an impact on antibody activity in vivo . 48 The presence of galactose and sialic acid is associated with anti-inflammatory properties of antibody. It remains to be determined whether milk immune complexes contain galactose and sialic acid and, if this is the case, whether they confer to these molecules immunosuppressive properties.
The increased protection afforded by milk OVA -Ig immune complexes as compared to free OVA may also result from a more efficient antigen presentation by tolerogenic antigen-presenting cell. Indeed, Fc -mediated or complement receptor-mediated presentation of antigen is much more efficient than passive pinocytosis. 48, 49 Accordingly, when normalized to OVA concentration, milk OVA -IgG immune complexes were at least 100-fold more efficient than free OVA at inducing the proliferation of OVA-specific TCR transgenic T cells in vitro ( Figure 6 and Supplementary Figure 3 ) . Accordingly, the role of other Fc R than Fc RIIb and complement receptor such as C1q remains to be determined in tolerance induction after transfer of immune complexes from mother to the pups. In addition to its critical role in the transport of immune complexes from the gut lumen to the intestinal mucosa, the FcRn may also enhance the presentation of Ag -Ig immune complexes by DCs, possibly by directing multimeric immune complexes to lysosomes. 50 Adoptive transfer experiments showed that naive antigenspecific newborn CD4 + T cells differentiated into FoxP3 + CD25 + T reg cells in mice breastfed by OVA-exposed sensitized mothers. Furthermore, protection afforded by OVA-exposed sensitized mothers was reduced, although not totally abolished, upon treatment with anti-CD25 mAb showing a role for FoxP3 + CD25 + T reg in neonatal tolerance induction upon transfer of milk immune complexes to the neonates. IL-10-secreting Tr1 lymphocytes might also have a role in tolerance induced in mice breastfed by OVA-exposed sensitized mothers as Tr1 were shown to be enriched in the gut. 51 However, Breastfeeding-induced tolerance in anti-CD25 monoclonal antibody (mAb)-treated mice. BALB / c pups were breastfed by unexposed or ovalbumin (OVA)-exposed sensitized mothers. When 6-week-old, the offspring were treated with anti-CD25 or isotypic control mAb, sensitized with OVA 1 week later, and challenged with OVA aerosols. Data show the total number of cells and frequency of eosinophils in bronchoalveolar lavage (BAL) fluid ( a ), serum levels of OVA-specific IgE content ( b ), and levels of IL-5 and IL-13 secreted by lung cells when incubated with OVA ( c ) in mice breastfed by unexposed (gray bars) or OVA-exposed (black bars) sensitized mothers treated with an isotypic control mAb, and unexposed (dashed white bars) or OVA-exposed (dashed black bars) sensitized mothers treated with an anti-CD25 mAb. Data are expressed as mean ± s.e.m. of two experiments with n = 6 -8 mice per group in each experiment * * * * P < 0.0001; * * * P < 0.001; * * P < 0.01.
our preliminary data showed that IL-10-deficient mice are equally protected upon breastfeeding by OVA-exposed sensitized mothers.
The presence of IgA in human breast milk is well documented. Maternal pathogen-specific IgA in breast milk are crucial to prevent respiratory and gut infections in the breastfed child. 7 IgA have also been associated with tolerance induction in both mice and humans. 17 -20 Here, we have observed that milk IgA were not necessary for tolerance induction. The role of IgG in human milk has been much less studied and furthermore, no study has investigated whether breast milk contains IgG immune complexes and if it does, how could these complexes influence the development of the newborn immune system. Feld1 -IgG 52 immune complexes have been found in maternal sera and cord blood, suggesting that allergens -IgG immune complexes might also be found in human milk. Because FcRn is expressed in the human intestine, it is possible that what we have observed in mice could be relevant in humans. This issue could possibly be addressed by performing clinical trials aimed at assessing if there is a correlation between the presence of airborne allergen in breast milk, its presence as free antigen or in the form of immune complexes and the development of asthma in the breastfed child. The identification of key parameters for tolerance induction in neonates may allow the elaboration of new guidelines for asthma primary prevention.
In conclusion, we believe that this study provides new insights on the mechanisms of tolerance induction in neonates and highlights that IgG immune complexes found in breast milk are potent inducers of oral tolerance.
METHODS
Mice . BALB / c mice and C57BL / 6 mice were purchased from the Centre d ' Elevage Janvier (Le Genest Saint Isle, France) and housed in our animal facility under SPF conditions. RAG-2-deficient mice were obtained from the Centre de Transg é n è se et Archivage d ' Animaux Mod è les (Orleans, France); DO.11.10 and OTII TCR transgenic mice from F. Powrie (Oxford, UK) and B. Malissen (Marseille, France), respectively; Fc RIIb-deficient mice from S. Verbeek (Leiden University, the Netherlands); and FcRn-deficient mice from D. Roopenian (Jackson laboratory, Bar Harbor, ME).
Sensitization and exposure of mothers to the antigen . For sensitization, 6-to 8-week-old BALB / c mice were sensitized 1 week apart by two consecutive intraperitoneal injections of 10 g of OVA (grade V; Sigma, Saint-Quentin, France) in 2 mg of alum (Pierce, Rockford, IL) ( Figure 1a ). Non-sensitized and sensitized mice were mated 2 days after the last injection. At delivery, pups from sensitized mothers were replaced by pups from non-sensitized mothers. For antigen exposure, mothers were exposed or not exposed to 0.3 % OVA (grade V; Sigma) aerosols for 20 min every other day starting 24 h after delivery until weaning using an ultrasonic nebulizer (Ultramed; Medicalia) connected to a 13,000 cm 3 box that served as the deposition chamber for the mice. Aerosols were given in groups of a maximum of 5 -10 mothers. During aerosol exposure, mothers were separated from their progeny. OVAspecific IgE and IgG1 were readily detected in the serum of OVA-sensitized mothers and their levels increased 2-to 3-fold upon exposure to OVA aerosols ( Supplementary Figure 1 ) . In addition, OVA-exposed sensitized mothers exhibited mild eosinophilic airway inflammation ( Supplementary Figure 1 ) . Where indicated, mothers were treated with 1 mg of anti-TGF-antibody (1D11 clone; ATCC, Manassas, VA) or isotypic control rat IgG1 (GL113; DNAX, Palo Alto, CA) twice a week or 100 g of anti-CCL-28 antibody (clone 134306; R & D Systems, Minneapolis, MN) 21 or isotypic ctrl rat IgG2b (clone 141945; R & D Systems) every other day from delivery until weaning. After treatment with antibody to TGF-, the TGF-1 content in milk was reduced at least sixfold (1.4 ± 0.3 to 0.2 ± 0.1 ng ml − 1 ; mean of four experiments ± s.d.).
Induction of allergic asthma in the progeny . Breastfed mice were sensitized at the age of 6 -8 weeks unless stated otherwise ( Figure 1a ) . Sensitization was performed by two intraperitoneal injections of 10 g of OVA in 2 mg of alum (Pierce) at day 0 and 7. Mice were exposed daily to 0.3 % OVA aerosols for 5 days starting 10 days after the second injection. Aerosol exposure was performed for 20 min using an ultrasonic nebulizer (Ultramed; Medicalia) connected to a 13,000 cm 3 box that served as the deposition chamber for the mice. When indicated, mice were injected with 0.5 mg of anti-CD25 mAb (PC61 clone; ATCC) or with rat IgG1 (GL113 clone; DNAX) 1 week before sensitization. In some experiments, mice were sensitized with 10 g LACK in 2 mg of alum and further exposed to 0.2 % LACK aerosols as described. 16 LACK was detoxified using an EndoTrap column (Profos, Regensburg, Germany) according to the manufacturer ' s instructions. Lipopolysaccharide levels were below 10 ng per mg of protein.
Airway hyperreactivity . Airway hyperreactivity was measured 1 day after the last aerosol by invasive plethysmography (emka Technologies, Paris, France) in response to inhaled methacholine (Sigma). For dynamic lung resistance and compliance, measurements were performed using a flexiVent apparatus (SCIREQ, Montreal, Canada). Mice were anesthetized (5 ml per kg body weight (ml kg − 1 ) of 10 % medetomidine (Pfizer, Paris, France) and 10 % ketamine (Merial, Lyon, France)), tracheotomized, paralyzed (5 ml kg − 1 of 1 % pancuronium bromide (Organon, Puteaux, France)) and immediately intubated with an 18-gauge catheter, followed by mechanical ventilation. Respiratory frequency was set at 150 breaths per min with a tidal volume of 0.2 ml, and a positive-end expiratory pressure of 2 ml H 2 O was applied. Increasing concentrations of methacholine (0 -24 mg ml − 1 ) were administered at the rate of 20 puffs per 10 s, with each puff of aerosol delivery lasting 10 ms, through a nebulizer aerosol system with a 2.5 -4 m aerosol particle size generated by a nebulizer head (Aeroneb; Aerogen, Dangan, Ireland). Baseline resistance was restored before administering the subsequent doses of methacholine. Serum and milk . Blood was harvested from mice by intracardiac puncture and serum was prepared by centrifugation (10,000 g , 10 min) using heparin-treated tubes (SARSTEDT, Marnay, France). Breast milk was collected from the stomach of 2-week-old pups 4 -6 h after OVA aerosol exposure of lactating mothers and diluted in 1 volume of PBS. Samples were spun down at 10,000 g for 10 min and the supernatant was collected and stored at − 20 ° C until analysis.
Antibody levels . Serum and milk were analyzed for the presence of OVA-specific or LACK-specific IgA, IgE, IgG1, and IgG2a by ELISA. For IgG1, MaxiSorp plates (Nunc, Roskilde, Denmark) were coated with OVA or LACK, saturated with 10 % fetal calf serum in PBS, and incubated with serial dilution of sera followed by biotinylated anti-IgG1 antibody (BD553-441; BD). For antigen-specific IgA, IgE and IgG2a plates were first coated with their respective capture mAb (BD), saturated with
